Table 10.

Recovery of peripheral B cell counts during the treatment period

Visit	Day	MMF Group			Placebo Group			Wilcoxon Test (P Value)
		No. of Patients	Mean (SD)	Median (min-max)	No. of Patients	Mean (SD)	Median (min-max)
0	Screening period	39	588.7 (573.9)	418 (22–3329)	39	534.8 (400.1)	421 (83–2040)	0.91
1	1	38	674 (454.9)	670.3 (7.2–1722.2)	36	609.9 (551.7)	534.2 (13.6–2384.2)	0.24
2	8	38	5.6 (7.6)	3 (0–35.3)	37	5.9 (10.2)	2.4 (0–50.4)	0.54
4	22	39	4.7 (8)	1.8 (0–34.2)	35	4 (8.5)	1.6 (0–43.7)	0.55
5	29	25	3.3 (5.2)	1.2 (0–22.5)	26	4.6 (9.8)	0.7 (0–44.7)	0.61
6	57	39	3.9 (5.7)	2 (0–28.6)	38	5.1 (11.7)	1.6 (0–67.3)	0.61
8	113	37	4.8 (9.5)	1.7 (0–51.2)	38	11.6 (36.6)	1.5 (0–206.3)	0.96
10	169	37	36.9 (84.1)	7.2 (0–454.4)	38	113.9 (228.8)	9.5 (0–797.2)	0.31
11	225	39	83 (85.3)	65 (0–376.3)	37	187.8 (269.2)	70.5 (0–1176.3)	0.38
12	281	39	182.5 (180.3)	119.6 (0–715)	34	310.7 (564.5)	136.7 (1.3–3015)	0.91
13	337	39	228.2 (162.8)	207.2 (0–670.1)	34	282.8 (322.4)	182.6 (5–1258)	0.80
14	393	36	278.3 (199.9)	267.9 (12.6–881.3)	32	379.5 (554.1)	201.9 (0.6–2826.3)	0.50
15	449	35	282.4 (185.9)	273.5 (7.6–834.6)	30	274 (291.7)	190 (0–1191.3)	0.28
16	505	35	276.6 (165.8)	267.3 (8–575)	29	253.2 (230)	214 (0–856.5)	0.19

min-max, minimum-maximum.